Compare Amphastar Pharmaceuticals Inc (AMPH) vs Invesco Ltd. (IVZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Invesco Ltd. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Invesco Ltd. trades at $28.98 (market cap $12.85B). The key difference: Invesco Ltd. is far larger — about 15.6× Amphastar Pharmaceuticals Inc's market cap, and Invesco Ltd. pays a 2.97% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | IVZ | |
|---|---|---|
Market Cap | $826.08M | $12.85B |
Sector | Health | Financials |
52-Week High | $30.81 | $29.44 |
52-Week Low | $16.87 | $16.74 |
Enterprise Value | $1.22B | $23.09B |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
IVZ trades at $28.98, up 1.29% today, with a bullish technical signal and analyst consensus price target of $29.79. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, while the company reported a net loss of $281.70 million in 2025. Positive cash flow from operations of $1.53 billion and a recent dividend payment of $0.22 per share highlight financial stability amid profitability challenges.
The outlook for IVZ is cautiously optimistic, supported by strong analyst buy ratings and improving assets under management, but weighed down by negative net income margins and competitive pressures in asset management. Key risks include execution on profitability and market volatility affecting AUM growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
